Top-News
Mittwoch,
04.11.2015 15:15
von
PR Newswire
| Aufrufe: 224
Law Offices of Marc S. Henzel Announces Investigations of Globus Medical, Inc., USA Technologies, Inc., Constant Contact, Inc., Dyax Corp, Hutchinson Technology and MedAssets, Inc.
Ein Verkaufsgespräch (Symbolbild).
pixabay.com
PR Newswire
MERION STATION, Pa., Nov. 4, 2015
MERION STATION, Pa., Nov. 4, 2015 /PRNewswire/ --
The Law Office is investigating Globus Medical, Inc. (GMED) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. According to a lawsuit filed, throughout the Class Period (2/26/14 thru 8/5/14) defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Globus Medical's relationship with a significant distributor was deteriorating; (2) such deterioration was negatively impacting Globus Medical's financial performance; and (3) as a result of the foregoing, defendants' statements about Globus Medical's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you would like to learn more about the investigation or you wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at Mhenzel@Henzellaw.com, or visit the firms website at www.henzellaw.com.
The Law Office is investigating USA Technologies, Inc. (USAT) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. According to a lawsuit filed, during the class period (9/29/14 thru 9/29/15) Defendants made false and/or misleading statements and/or failed to disclose that: (1) there were significant deficiencies in both the design and operating effectiveness of USA Technologies' internal control over financial reporting; (2) the combined deficiencies represented a material weakness in internal control; (3) due to these deficiencies, USA Technologies' procedures failed to identify a large number of uncollectible small balance accounts; and (4) as a result, USA Technologies' public statements were materially false and misleading at all relevant times." On September 29, 2015, USA Technologies revealed it was unable to file its annual report for the fiscal year ended June 30, 2015 on Form 10-K with the SEC. On this news, shares of USA Technologies fell $0.28, or 10.1%, to close at $2.49 on September 30, 2015.
If you would like to learn more about the investigation or you wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at Mhenzel@Henzellaw.com, or visit the firms website at www.henzellaw.com.
ARIVA.DE Börsen-Geflüster
Kurse
 |
 |
 |
 |
 |
 |
 |
Constant Contact, Inc. (Nasdaq: CTCT)
The firm is investigating the fairness of the sale of Constant Contact, Inc. (Nasdaq: CTCT) to Endurance International Group Holdings, Inc. (EIGI). The two companies have entered into a definitive agreement under which Endurance International will acquire all of Constant Contact's outstanding shares of common stock for $32.00 per share in cash, valuing Constant Contact at approximately $1.1 billion. The value represents a multiple of 12x 2015 estimated adjusted EBITDA, including cash on its balance sheet. Including expected synergies, this represents a multiple of 7x 2015 estimated adjusted EBITDA. The offer represents a premium of approximately 23 percent over Constant Contact's closing price of $26.10 on October 30, 2015.
If you would like to learn more about the investigation or you wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at Mhenzel@Henzellaw.com, or visit the firms website at www.henzellaw.com.
The firm is investigating potential legal claims against the board of directors of Dyax Corp. (Nasdaq: DYAX) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Shire plc (NASDAQ: SHPG).
It was announced that Shire will acquire Dyax for $37.30 in cash per Dyax share, for aggregate upfront consideration of approximately $5.9 billion. Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 in HAE, representing a potential additional $646 million in aggregate contingent consideration.
If you would like to learn more about the investigation or you wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at Mhenzel@Henzellaw.com, or visit the firms website at www.henzellaw.com.
Hutchinson Technology (Nasdaq: HTCH)
The firm is investigating the fairness of the sale of Hutchinson Technology (Nasdaq: HTCH) to TDK Corporation for $3.62 per share in cash and up to $0.38 cash additional consideration per share.
The companies announced that they have entered into a definitive merger agreement under which TDK will acquire all of the outstanding shares of common stock of HTI for base consideration of US$3.62 per share, plus additional consideration of up to US$0.38 per share, depending on the level of cash (subject to certain adjustments) less any outstanding borrowings on HTI's revolving line of credit ("net cash") held by HTI as of the last day of the fiscal month immediately preceding the closing date. The amount of additional consideration, if any, will equal approximately US$0.01 per share for each US$500,000 of HTI's net cash over US$17.5 million as of the measurement date.
If you would like to learn more about the investigation or you wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at Mhenzel@Henzellaw.com, or visit the firms website at www.henzellaw.com.
MedAssets, Inc. (Nasdaq: MDAS)
The firm is investigation the fairness of the sale of MedAssets, Inc. (Nasdaq: MDAS) to Pamplona Capital Management for $31.35 per share.
Pamplona Capital Management (Pamplona) announced it had agreed to acquire MedAssets (NASDAQ:MDAS). Pamplona is purchasing MedAssets for $31.35 per share, which represents a total enterprise value of approximately $2.7 billion for the acquisition.
If you would like to learn more about the investigation or you wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at Mhenzel@Henzellaw.com, or visit the firms website at www.henzellaw.com.
The Law Offices of Marc S. Henzel is a national shareholder litigation firm representing shareholders & investors in various areas of securities laws including but not limited to; class actions, derivatives, transactional (buyouts/mergers/acquisitions) and FINRA & NYSE Arbitrations.
Attorney advertising. © 2015 Law Offices of Marc S. Henzel. The law firm responsible for this advertisement is Marc S. Henzel. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Law Offices of Marc S. Henzel
Marc S. Henzel
Email: Mhenzel@Henzellaw.com
Phone 610-660-8000
Website: www.henzellaw.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/law-offices-of-marc-s-henzel-announces-investigations-of-globus-medical-inc-usa-technologies-inc-constant-contact-inc-dyax-corp-hutchinson-technology-and-medassets-inc-300171809.html
SOURCE Law Offices of Marc S. Henzel
Werbung
Mehr Nachrichten zur Shire ADR Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
